Welcome to our dedicated page for Ionis Pharmaceuticals SEC filings (Ticker: IONS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, along with AI-powered summaries to help interpret complex documents. As a biotechnology issuer focused on RNA-targeted medicines, Ionis uses filings such as Forms 8-K, 10-Q and 10-K to report clinical milestones, regulatory events, financing transactions and operating results.
Recent Form 8-K filings illustrate how Ionis communicates material developments. The company has furnished press releases on pivotal Phase 3 CORE and CORE2 results for olezarsen in severe hypertriglyceridemia, positive pivotal data for zilganersen in Alexander disease, and FDA approval of DAWNZERA (donidalorsen) for prophylaxis to prevent attacks of hereditary angioedema. Other 8-Ks describe FDA Breakthrough Therapy designations, European regulatory opinions and key clinical readouts across neurology and cardiometabolic programs.
Ionis also uses current reports to disclose capital markets activity. One 8-K details the issuance of 0.00% Convertible Senior Notes due 2030, including the terms of the indenture, conversion mechanics, redemption provisions, events of default and use of proceeds, such as repurchasing earlier convertible notes and funding general corporate purposes. Additional filings cover quarterly financial results, where the company presents both GAAP and non-GAAP measures, and governance or contractual matters like advisory services agreements.
On this page, Stock Titan connects directly to EDGAR to surface new Ionis filings as they are posted. AI-powered summaries help explain lengthy documents, highlighting items such as clinical trial outcomes, regulatory status updates, financing terms, risk factor changes and other key disclosures. Investors can quickly locate annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and other relevant filings, and use the AI analysis to understand how each document may relate to Ionis’ RNA-targeted pipeline, marketed medicines and capital structure.
Brett P. Monia, Chief Executive Officer and Director of Ionis Pharmaceuticals (IONS), reported multiple transactions on 09/03/2025 that offset each other, resulting in no net change to total common shares held. On that date the reporting person acquired 203,814 shares through exercises and market purchases and sold 203,814 shares under a Rule 10b5-1 trading plan adopted August 13, 2024. The filings show weighted-average sale prices in three ranges: $58.57–$59.55, $59.60–$60.57, and $60.61–$61.48. Following the transactions the reporting person beneficially owned 180,009 common shares. The Form 4 also lists exercises of non-qualified stock options at strike prices of $32.60, $37.58, and $53.77, with resulting increases in underlying common shares reported in Table II.
Joseph Klein III, a director of Ionis Pharmaceuticals, reported multiple transactions dated 09/03/2025. The filing shows two non-derivative acquisitions recorded as 16,000 and 12,000 shares of common stock reported with transaction code M and price listed as $0.0, each noted as indirectly owned by a trust. On the same date the form records a sale of 28,000 common shares at $60 per share, with an explanatory note stating the sale was made pursuant to a Rule 10b5-1 trading plan adopted January 3, 2024. The report also lists 16,346 shares held directly and 100 shares held indirectly by his son, with the filer disclaiming beneficial ownership of the son's shares.
Joseph Klein III, a director of Ionis Pharmaceuticals, reported multiple transactions on 09/03/2025. The filing shows option exercises resulting in receipt of common stock and contemporaneous sales executed under a Rule 10b5-1 trading plan. Specifically, the report lists exercises of options that generated 12,000 and 16,000 shares credited to a trust, and a sale of 28,000 shares at $60 per share pursuant to the 10b5-1 plan. The filing also reports a disposition of 16,346 shares and notes 100 shares held by his son for which he disclaims beneficial ownership. All transactions are reported as indirect holdings through a trust except the 100 shares held by his son.
Richard S. Geary, Executive Vice President and Chief Development Officer of Ionis Pharmaceuticals (IONS), reported the sale of 10,000 shares of common stock on 09/02/2025. The shares were sold at a weighted average price of $50.3671 per share (individual trades ranged from $50.01 to $50.92). After the reported disposition, Mr. Geary beneficially owns 79,657 shares. The filing states the sales were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 6, 2025, and the filer offers to provide trade-level detail on request.
Shannon L. Devers, EVP & Chief Human Resources Officer of Ionis Pharmaceuticals (IONS), reported multiple transactions on September 3, 2025. The filing shows sales of 3,162 shares at a weighted average price of $61.0192 reported as executed under a Rule 10b5-1 trading plan adopted September 3, 2024. The reporting person also acquired 2,234 shares and acquired by option exercise 928 shares at stated prices.
The Form 4 lists two non-qualified stock option exercises that vest from 01/03/2023 and 01/03/2024 with expiration dates in 2032 and 2033 and shows 15,009 shares held after the sale.
Joseph H. Wender, a director of Ionis Pharmaceuticals, Inc. (IONS), reported sales of company common stock under a Rule 10b5-1 trading plan. On 09/02/2025 he sold 11,200 shares at a weighted average price of $55.0386 and 5,600 shares at a weighted average price of $57.5311, and on 09/03/2025 he sold 11,200 shares at a weighted average price of $60.1383. Following those transactions, the filing reports beneficial ownership levels of 125,635, 120,035 and 108,835 shares respectively, each listed as held indirectly by trust. The Form 4 states the trades were made pursuant to a 10b5-1 plan adopted December 16, 2024, and provides price ranges for the multiple executions behind each weighted average.
Joseph T. Baroldi, Executive Vice President and Chief Business Officer of Ionis Pharmaceuticals (IONS), reported multiple transactions dated 09/03/2025. The filing shows purchases/issuances of non-qualified stock options with a $31.80 exercise price totaling 32,800 options (three grants/exercises of 2,800, 15,000 and 15,000) that underlie common stock. On the same date the reporting person sold 32,800 common shares in multiple transactions at weighted average prices of $62.0101 and $59.0864 as noted. The Form 4 states the sales were made pursuant to a Rule 10b5-1 trading plan adopted May 2, 2025. Following the reported transactions, the filing lists various beneficial ownership totals and discloses 3,071 shares indirectly owned by spouse.
Patrick O'Neil, EVP, CLO & General Counsel of Ionis Pharmaceuticals (IONS), filed a Form 4 reporting multiple transactions on September 2–3, 2025. The filing shows exercises of non-qualified stock options and contemporaneous sales executed under a Rule 10b5-1 trading plan adopted May 2, 2025. Reported option exercises include 13,050 shares at a $32.60 strike, 14,000 at $37.58, and 49,800 at $53.77. Reported sales under the 10b5-1 plan include 13,050 shares at a weighted average $54.5148, 65,475 shares at a weighted average $60.89, and 11,375 shares at a weighted average $61.42. The Form discloses the number of shares beneficially owned following each transaction line as reported in the filing.
C. Frank Bennett, EVP and Chief Scientific Officer of Ionis Pharmaceuticals (IONS), reported multiple transactions in early September 2025. He sold shares under a Rule 10b5-1 trading plan adopted May 13, 2025, and reported sales on 09/02/2025 and 09/03/2025 at weighted-average prices of $49.14 and ranges around $60.25–$61.995 and $61.26–$61.995 as disclosed. On 09/03/2025 he also acquired 46,800 shares by exercise/conversion of non-qualified stock options with a $53.77 exercise price. Following the reported activity, his beneficial ownership is reported as 88,679 shares.
Joseph Loscalzo, a director of Ionis Pharmaceuticals (IONS), reported paired transactions on 09/03/2025. He exercised 16,000 non-qualified stock options with an exercise price of $24.42 (options originally granted 07/01/2017, expiring 06/30/2026) and thereby acquired 16,000 shares. The same day he sold 16,000 shares under a Rule 10b5-1 trading plan adopted August 13, 2024, at a weighted-average price of $60.1482 (sales ranged from $60.00 to $60.57). The Form 4 shows 36,330 shares beneficially owned following these transactions.